Disclaimer: This article was developed with the assistance of generative AI tools.
Abstract
Clinicians—nurse practitioners, physician associates, pharmacists, and physicians—are uniquely equipped to lead in Medical Science Liaison (MSL) roles because they bring the human experience of care into the science of communication. This editorial explores how the clinical mindset, grounded in empathy, ethics, and systems thinking, translates complex data into meaningful dialogue and trust within the medical community. Drawing from real-world examples and recent literature, it argues that clinicians do not leave patient care when entering industry; rather, they expand it—advocating earlier in the chain of influence to shape evidence generation, health equity, and patient-centered innovation. Clinical experience provides not only credibility but also the ability to discern context, interpret the unsaid, and safeguard integrity in scientific exchange. As the pharmaceutical and biotech landscapes evolve, clinician-MSLs serve as living bridges between data and humanity, ensuring that science remains accountable to the lives it is meant to improve.
Keywords: Clinicians in industry; medical science liaison; nurse practitioners; medical affairs; scientific communication; health equity
Main Article
When I first graduated from nursing school, my purpose was clear: listen, heal, and advocate. I never imagined that one day I’d trade patient charts for medical slide decks. Yet the through-line remains the same—connection. In every role, whether at the bedside or in a boardroom, I am still translating science into something deeply human and usable. That translation is the heartbeat of the Medical Science Liaison (MSL) role, and it is why clinicians—nurse practitioners, physician associates, pharmacists, and physicians—are uniquely equipped to lead it.
Clinicians bring something that cannot be trained in orientation or replicated by analytics: the lived experience of care. We’ve heard the tremor in a caregiver’s question and watched evidence collide with access. That grounding in humanity turns data into understanding. As Theron et al. (2021) observed, effective MSL practice depends on scientific exchange “grounded in clinical realities, not abstract trial results.” Clinicians already live that reality.
The MSL role is often described as a bridge between industry and healthcare, but clinicians make that bridge a living opportunity. We carry the rhythm of the hospital, the pace of primary care, and the gravity of real-world outcomes. When an NP, PA, or pharmacist transitions into industry, every conversation becomes more authentic. Clinical background allows us to translate endpoints into meaning—moving from “risk reduction” to “reduced readmissions,” from “efficacy data” to “a patient getting back to work.”
A 2023 MSL Journal feature noted that clinicians entering industry impact “hundreds to thousands of lives at a time” by expanding their reach beyond direct care (Wilson, 2023). That expansion is not a departure from patient care; it is an evolution of it. Clinician-MSLs extend advocacy upstream—into the design of trials, the language of education, and the frameworks of equity.
Trust is the MSL’s currency, and credibility is its foundation. Clinicians don’t borrow credibility—they embody it. Years of synthesizing complex information under pressure train us to read both data and people. We instinctively recognize hesitation behind a question, skepticism behind a tone, or curiosity behind silence. That sensitivity—the ability to translate what’s unsaid—is the clinician’s superpower in scientific exchange. We can detect understanding, hesitation, and true by-in from the clinicians we interact with.
According to MSL Consultant (2025), “the strongest MSLs connect not by overwhelming with data, but by interpreting data through the lens of real-world practice.” This is exactly what clinicians do best. When we discuss an emerging therapy, we think in workflows, comorbidities, and community context-how will this impact not only the patients but the clinician’s time? Our credibility comes not from the badge we wear but from the bedside stories we carry.
In a field where the line between education and promotion must remain crystal clear, clinicians serve as ethical anchors. Our professional codes—ANA, AMA, APhA—teach that transparency is not optional; it is care in another form. We bring that ethos into every scientific conversation.
The MSL Society (2024) guidelines reaffirm that MSLs must operate as non-promotional scientific peers, prioritizing accuracy, balance, and patient benefit. Clinicians, trained to uphold patient welfare above all else, naturally align with these standards. We are not just messengers of data—we are guardians of integrity.
Clinicians think in systems. We see how a therapy interacts with electronic health records, staffing shortages, and reimbursement realities. That system’s awareness enables clinician-MSLs to anticipate barriers before they appear. It also helps connect medical affairs strategies to public-health goals—like trial diversity, patient adherence, and equitable access.
A 2023 MSL Journal commentary on clinician transitions emphasized that those from clinical backgrounds excel in field medical strategy because they can “connect micro-level patient insight with macro-level health outcomes” (Bishop, 2023). That ability is precisely what the industry needs as the landscape becomes more data-driven yet still human-dependent.
The myth persists that moving from clinical care to industry leaves patients. In truth, it is advocating earlier in the chain of impact—where data decisions determine care realities. Clinician-MSLs ensure that science serves diverse communities, that educational materials reflect cultural humility, and that evidence generation includes the populations most affected by disease.
We are not stepping away from care; we are scaling it. The same compassion that guided our clinical hands now guides our scientific voices. Every slide deck, every field exchange, and every investigator dialogue is an act of advocacy—one that shapes what reaches patients tomorrow.
The best MSLs are more than scientific experts; they are interpreters of meaning. Clinicians possess the empathy, ethics, and systems understanding to ensure that innovation remains tethered to humanity. As industry evolves toward more equitable, data-rich, patient-centric models, clinician-MSLs will be essential navigators.
The clinician’s compass—anchored in care and guided by integrity—keeps science aligned with its true purpose: improving lives. That is why those who have cared at the bedside are best suited to lead in the science of care.
References
Bishop, L. (2023, October 5). Transitioning from clinical practice to medical science liaison: Lessons in empathy and evidence. The MSL Journal. https://themsljournal.com/article/transitioning-from-clinical-practice-to-msl
Medical Science Liaison Society. (2024). Global guidelines for medical science liaison excellence. The MSL Society. https://themsls.org/msl-guidelines
MSL Consultant. (2025). Understanding the role of a medical science liaison and what they do all day. MSL Consultant. https://www.mslconsultant.com/post/what-is-a-medical-science-liaison-msl-and-what-do-they-do-all-day-1
Theron, P., et al. (2021). Promoting best practices for medical science liaisons: A position paper. Journal of Medical Science Liaison Practice, 3(1), 14–21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8492581
Wilson, T. (2023, July 18). I am a nurse practitioner—why I chose industry. The MSL Journal. https://themsljournal.com/article/i-am-a-nurse-np-why-i-chose-industry
About the author:
Tracy R. Wilson, DNP, FNP-C
Dr. Tracy R. Wilson has over 23 years of experience in healthcare and patient advocacy, with expertise in clinical education, family nursing, and interdisciplinary course design. She holds a Doctor of Nursing Practice from Belmont University, a Post-master FNP certification from the University of Kentucky, and a Master of Science (MS) in Bioethics from Tulane School of Medicine, as well as an MS in Nursing Education from Bellarmine University.
Currently, she works as a Medical Science Liaison at ARS Pharma, focusing on an FDA-approved product for allergies and anaphylaxis, providing medical education to Key Opinion Leaders and healthcare professionals. Previously, as a field medical director for antivirals at Pfizer (2019-2024), Dr. Wilson launched six new products and contributed to healthcare disparity initiatives. She is a recognized speaker and panelist, with numerous awards, including being inducted as a Fellow of the American Association of Nurse Practitioners, the President’s Award from the National Black Nurse Practitioner Association, and the Patient Impact Award for Pharmaceuticals.
She was recently awarded the Daisy Award for Nurses Advancing Health Equity. Dr. Wilson was also nominated as an MSL of the Year finalist and nominated for Young Black Pharma’s Cultivate, Inspire, Connect Award. She will be inducted in December as a Fellow of the Academy of Diversity Nurse Leaders. Dr. Wilson has redefined what it means to be an international nurse leader—uniting science, advocacy, and innovation to bring nasal epinephrine to market. Her groundbreaking work is helping to revolutionize emergency anaphylaxis care by increasing access, improving safety, and reducing reliance on injectable epinephrine, all while minimizing infection risks and administration errors. As both a nurse scientist and industry nurse practitioner, her powerful voice and clinical insight have already accelerated adoption across healthcare systems worldwide—proving that “when nurses lead, the world listens.”
Have an opinion on this article? Send a message to the editor.